- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02564393
Induction of Neutrophilic Traps ( NETs ) by the Environment and Infectious Inflammatory Lung Cystic Fibrosis (MucoNETs)
Secretion Induction of Neutrophil Extracellular Traps (NETs)in Inflammatory and Infectious Environment of Mucoviscidose
The study is defined in 3 stages of in vitro assays :
Phase 1 : Secretion of NETs in response to lung disease and their secretion of factors.
This is a transversal study in which we compare :
- Producing NETs (DNA and proteases ) by neutrophils purified from sputum and blood of patients
- Producing NETs (DNA and proteases ) by purified neutrophils in the blood of patients and blood of control subjects
Phase 2: Mechanisms of activation of NETs secretory pathways . This phase will identify receptors (TLR ) involved in the secretion of NETs and analyze the involvement of dependent transduction pathways calcium and PKC . It will be performed on control blood neutrophils.
Phase 3: Analysis of cell death ( NETose )
This is a transversal study that will analyze :
the mode of cell death of neutrophils purified blood and sputum of patients and control blood neutrophils by flow cytometry and transmission electron microscopy .
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Tours, France
- CHRU de Tours
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Patients :
- Men or women over 18
- Patients with mucoviscidose in stable condition, i.e. not having presented an acute push of bronchopulmonary attack requiring a antibiothérapie or a hospitalization for treatment of its disease during the 2 previous weeks
- Signed consent
Volunteers :
- Men or women over 18
- Without respiratory antecedent nor known respiratory pathology
- Signed consent
Exclusion Criteria:
Patients :
- In exclusion period of an other study
Volunteers :
- In exclusion period of an other study
- Antibiotic treatment and/or anti-inflammatory drug (AINS or corticoids) in the 2 weeks before inclusion in the study
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
|---|
|
T
Control
|
|
A
Adult with cystic fibrosis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
the DNA concentration secreted into the extracellular environment neutrophil activated
Time Frame: 1 hour
|
1 hour
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PHAO09-PD / MucoNETs
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystic Fibrosis
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
Dartmouth-Hitchcock Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingCystic Fibrosis (CF) | Cystic Fibrosis Gastrointestinal DiseaseUnited States
-
Haisco Pharmaceutical Group Co., Ltd.RecruitingNon-cystic Fibrosis BronchiectasisChina
-
AstraZenecaRecruitingNon-cystic Fibrosis BronchiectasisChina
-
Alexander HorsleyRecruitingCystic Fibrosis (CF) | Cystic Fibrosis Pulmonary ExacerbationUnited Kingdom
-
Reistone Biopharma Company LimitedRecruiting
-
University of Colorado, DenverCystic Fibrosis FoundationTerminatedCystic Fibrosis-related Diabetes | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in ChildrenUnited States
-
Royal College of Surgeons, IrelandThe Hospital for Sick Children; Imperial College London; Erasmus Medical Center; University College Dublin and other collaboratorsActive, not recruitingCystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver DiseaseUnited Kingdom, Ireland
-
Herlev and Gentofte HospitalCopenhagen University Hospital, DenmarkActive, not recruitingMyocardial Infarction | Heart Diseases | Heart Failure | Stroke | Cystic Fibrosis | Heart Failure, Diastolic | Heart Failure, Systolic | Left Ventricular Dysfunction | Cystic Fibrosis-related Diabetes | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of Pancreas | Cystic Fibrosis, Pulmonary | Cystic...Denmark
-
Alexander HorsleyRecruitingCystic Fibrosis (CF) | Cystic Fibrosis Pulmonary ExacerbationUnited Kingdom